Pathobiology research at EORTC aims to identify and validate biomarkers across cancer types that can be used to develop new or more targeted treatments.
EORTC has implemented a cross group policy for biobanking
EORTC research has resulted in the clinical qualification of uPA/PAI-1 as a class 1 level-of-evidence biomarkers for the prognosis of node-negative breast cancer patients. These biomarkers were subsequently recommended by national and international guidelines.
It has also contributed to the validation of gene-expression profiles and to the discovery of mechanisms of breast cancer metastasis leading to more personalised treatment for this cancer.
In addition, our pathobiology research has guided the development of robust, reliable and cost-effective assays applicable for routine clinical testing.
Martin Luther Universitaet
Halle , Germany
Radboud University Medical Center Nijmegen